Tirzepatide: difference between revisions
Diff·revision 10 → 11·05:04, 17 Oct 2024
Difference between revision 10 and revision 11 of Tirzepatide. 1 line changed; the page grew by 137 bytes.
| Revision 10 — 20:00, 28 Sep 2024 SelectTrialSam (talk) add category for the drug class 4,706 bytes +840 | Revision 11 — 05:04, 17 Oct 2024 TelehealthTruus (talk) add the receptor targets to the lead sentence 4,843 bytes +137 | ||
|---|---|---|---|
| 13 | | Residues = 39 | 13 | | Residues = 39 |
| 14 | }} | 14 | }} |
| + | 15 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} | |
| 15 | 16 | ||
| 16 | '''Tirzepatide''' is a 39-residue synthetic peptide that activates both the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]], making it the first [[Dual incretin agonist|dual incretin agonist]] to reach the market. Its backbone is derived from GIP rather than from GLP-1, and it is described in the literature as GIP-biased, with greater potency at the GIP receptor than at the GLP-1 receptor.{{r|coskun2018}} | 17 | '''Tirzepatide''' is a 39-residue synthetic peptide that activates both the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]], making it the first [[Dual incretin agonist|dual incretin agonist]] to reach the market. Its backbone is derived from GIP rather than from GLP-1, and it is described in the literature as GIP-biased, with greater potency at the GIP receptor than at the GLP-1 receptor.{{r|coskun2018}} |